1 Jul 2019
PHARMAZEN LIMITED v ANAGENIX IP LIMITED [2019] NZHC 1520
- Citation
- [2019] NZHC 1520
- Court
- High Court
Applying the notional fair-use test of s25(1)(b) the Court concluded the goods are similar, the marks are similar in visual and aural impression (notably sharing the prefix 'ACT-' and overall sound), and a significant number of persons would likely be deceived or confused by ActiPhen; absence of Anagenix's current New Zealand sales is irrelevant to the s25(1)(b) inquiry though relevant to s17(1)(a); accordingly the Commissioner's decision to refuse registration under s25(1)(b) was upheld and the appeal dismissed.